Alice Indini

[Alice Indini @AliceIndini]

What is the real benefit of adjuvant therapy in stage II and III melanoma? A group of experts critically reviewed the results so far reported. A must read article to guide therapeutic choices in a debated setting!
#IAmPractisingOncologist #melanoma https://t.co/RiXBMuLmAz

[Benedetta Pellegrino @bpellegrino89]

Great job, #Iampractisingoncologist! We r the @esmo_eur_oncology commitee involved in feeling the gap between research and daily clinical practice. If you have a full 8-hours clinic and look4a way to be updated on what’s going on in the oncology field, welcome on board!

[ESMO - Eur. Oncology @myESMO]

Alexios Matikas, OncologyPRO Working Group Member & ESMO #YoungOncologist Committee Member, on why OncologyPRO is an essential tool to help oncologists in their #dailypractice, thanks to its accessibility, ease of use, and content depth.
https://t.co/e41Fmw7WvT

#oncology

[Alberto Cunquero @alcunto]

Great job from the Practising Oncologist Working Group! Very useful!!!!

[ESMO - Eur. Oncology @myESMO]

Calling all practising oncologists 📢 Take the ESMO Practising Oncologists Working Group survey so we can better understand your practice needs & opinions on current products. https://t.co/cnL3m1hH1t

@brasiuniene @DrMeredithGT @LazarPo31787807 @BennounaJaafar @G_LipositsMD

[Alice Indini @AliceIndini]

@brasiuniene I’ll see you there!

[Mario Mandala @MandalaMario]

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. https://t.co/7zKip3flFq

[Florentia Dimitriou, MD PhD PD @FDimitriouMD]

Our study on #mucosal #melanoma is now online in @Annals_Oncology - Although retrospective, this study represents the largest report to date analyzing the efficacy of ICIs in this rare cancer that carries a poor prognosis. Here are some key points:

[ESMO - Eur. Oncology @myESMO]

Soft Tissue #Sarcomas Webinar ⏰ 29/3, 18:30 CEST Registration open for this live discussion of a real-world case. Live viewers: certificate of attendance & 1 ESMO-MORA point
Full info 🔗 https://t.co/9c6MKZ12OA

@AliceIndini @SilviaStacchia @pawel_sobczuk @jeanyvesblay #scmsm

[ESMO - Eur. Oncology @myESMO]

#ESMOPreceptorship on Molecular #CancerBiology for Practising Oncologists & #Cancer Treatment De-escalation 2022: Multidisciplinary management, standards of care & future perspectives
https://t.co/BAQwLKuQ2Z

@BennounaJaafar @brasiuniene @PietDirix @G_LipositsMD @LazarPo31787807

[Cancer Discovery @CD_AACR]

Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. https://t.co/bSer4maIjF @Ludwig_Cancer

[Hussein Tawbi, MD, PhD @HTawbi_MDPhD]

On behalf of my colleagues, so excited to bring a new and safer immune checkpoint inhibitor combination to our patients with advanced melanoma, Relatlimab (anti-LAG3) with nivolumab improves PFS, minor increase in toxicity, new frontiers for #Immunotherapy https://t.co/Sp2XCk7xzk

[Meredith GTrinidad, MD @DrMeredithGT]

👉 Check out the @myESMO Practicing Oncologists Working Group's new series of Spotlight presentations featuring highlights from #ESMO21

https://t.co/WWynrfLLBH

[Mario Mandala @MandalaMario]

Mucosal melanomas: molecular profile and therapy. What physicians need to know!!

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties https://t.co/XXZ0BmOxFg @SripadRam

[Alice Indini @AliceIndini]

Do not miss!

https://t.co/SilA9BnU3E